Compounds > allotetrahydrocortisol
Page last updated: 2024-12-07

allotetrahydrocortisol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

allotetrahydrocortisol: RN given refers to (3alpha,5alpha,11beta)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID92748
CHEBI ID89627
SCHEMBL ID5609666
MeSH IDM0049046

Synonyms (72)

Synonym
allopregnane-3.alpha.,17.alpha.,21-tetrol-20-one
compound f, allotetrahydro-
wintersteiner's compound d
allocortisol, tetrahydro-
nsc86469
.alpha.-thf
nsc-86469
302-91-0
allotetrahydrocortisol
cortisol, allotetrahydro-
athf
5.alpha.-tetrahydrocortisol
3.alpha.,5.alpha.-tetrahydrocortisol
allo-tetrahydrocortisol
pregnan-20-one,11,17,21-tetrahydroxy-, (3.alpha.,5.alpha.,11.beta.)-
allotetrahydrocompound f
kendall's compound c
tetrahydroallocortisol
5.alpha.-pregnan-20-one,11.beta.,17,21-tetrahydroxy-
allo-3.alpha.-tetrahydrocortisol
reichstein's substance c
5a-tetrahydrocortisol
LMST02030200
2-hydroxy-1-[(3r,5s,8s,9s,10s,11s,13s,14s,17r)-3,11,17-trihydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,14,15,16-tetradecahydrocyclopenta[a]phenanthren-17-yl]ethanone
allopregnane-3alpha,11beta,17alpha,21-tetrol-20-one
5alpha-tetrahydrocortisol
pregnan-20-one, 3,11,17,21-tetrahydroxy-, (3alpha,5alpha,11beta)-
3-alpha,11-beta,17-alpha,21-tetrahydroxy-5-alpha-pregnan-20-one
a30u7u312e ,
3alpha,5alpha-tetrahydrocortisol
allo-3alpha-tetrahydrocortisol
alpha-thf
nsc 86469
einecs 206-131-1
5alpha-pregnan-20-one, 3alpha,11beta,17,21-tetrahydroxy-
unii-a30u7u312e
allo-3|a-tetrahydro cortisol
allopregnane-3.alpha.,11.beta.,17.alpha.,21-tetrol-20-one
pregnan-20-one, 3,11,17,21-tetrahydroxy-, (3.alpha.,5.alpha.,11.beta.)-
(3.alpha.,5.alpha.,11.beta.)-3,11,17,21-tetrahydroxypregnan-20-one
3.alpha.-allotetrahydrocortisol
3.alpha.,11.beta.,17,21-tetrahydroxy-20-oxo-5.alpha.-pregnane
3.alpha.,11.beta.,17,21-tetrahydroxy-5.alpha.-pregnan-20-one
17-(1-keto-2-hydroxyethyl)androstane-3,11,17-triol
allopregnane-3.alpha.,11.beta.,17.alpha.,21-tetrol-20-one [mi]
SCHEMBL5609666
CHEBI:89627
AODPIQQILQLWGS-FDSHTENPSA-N
5a-pregnane-3a,11b,17a,21-tetrol-20-one
allotetrahydro-cortisol
tetrahydro-allocortisol
5a-pregnane-3a,11b,17a,21-tetraol-20-one
allo-3a-tetrahydrocortisol
3alpha, 5alpha-tetrahydrocortisol
allotetrahydro-compound f
3a,11b,17,21-tetrahydroxy-5a-pregnan-20-one
allopregnane-3a,11b,21-tetrol-20-one
3a,11b,17a,21-tetrahydroxy-5a-pregnan-20-one
a-thf
3a,5a-tetrahydrocortisol
allopregnane-3a,11b,17a,21-tetrol-20-one
3a-allotetrahydrocortisol
Q27161825
3,11,17,21-tetrahydroxypregnan-20-one
allo-3alpha-tetrahydro cortisol
DTXSID80861575
2-hydroxy-1-((3r,8s,9s,10s,11s,13s,14s,17r)-3,11,17-trihydroxy-10,13-dimethylhexadecahydro-1h-cyclopenta[a]phenanthren-17-yl)ethanone
HY-113215
CS-0059329
allo-3?-tetrahydro cortisol
PD126220
AKOS040740675

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" The aim of this study was to determine whether in major depression changes in the activity patterns of local modulators of glucocorticoid action might contribute to an increase in cortisol bioavailability and if they change during antidepressant treatment and clinical response."( Cortisol metabolism in depressed patients and healthy controls.
Deuschle, M; Frankhauser, P; Gilles, M; Hamann, B; Kopf, D; Lederbogen, F; Lewicka, S; Onken, V; Römer, B; Schilling, C, 2009)		0.35
" These changes suggest an increase in cortisol bioavailability within tissues."( Cortisol metabolism in depressed patients and healthy controls.
Deuschle, M; Frankhauser, P; Gilles, M; Hamann, B; Kopf, D; Lederbogen, F; Lewicka, S; Onken, V; Römer, B; Schilling, C, 2009)		0.35
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
corticosteroid hormoneAny of a class of steroid hormones that are produced in the adrenal cortex.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Glucocorticoid biosynthesis1411

Research

Studies (38)

TimeframeStudies, This Drug (%)All Drugs %
pre-199012 (31.58)18.7374
1990's7 (18.42)18.2507
2000's10 (26.32)29.6817
2010's9 (23.68)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.73

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.73 (24.57)
Research Supply Index3.71 (2.92)
Research Growth Index4.44 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.73)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (2.56%)5.53%
Reviews0 (0.00%)6.00%
Case Studies5 (12.82%)4.05%
Observational0 (0.00%)0.25%
Other33 (84.62%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
flutamide
Flutamide: An antiandrogen with about the same potency as cyproterone in rodent and canine species.		1.9510(trifluoromethyl)benzenes;
monocarboxylic acid amide		androgen antagonist;
antineoplastic agent
mianserin
Mianserin: A tetracyclic compound with antidepressant effects. It may cause drowsiness and hematological problems. Its mechanism of therapeutic action is not well understood, although it apparently blocks alpha-adrenergic, histamine H1, and some types of serotonin receptors.. mianserin : A dibenzoazepine (specifically 1,2,3,4,10,14b-hexahydrodibenzo[c,f]pyrazino[1,2-a]azepine) methyl-substituted on N-2. Closely related to (and now mostly superseded by) the tetracyclic antidepressant mirtazapinean, it is an atypical antidepressant used in the treatment of depression throughout Europe and elsewhere.		2.0510dibenzoazepineadrenergic uptake inhibitor;
alpha-adrenergic antagonist;
antidepressant;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
geroprotector;
H1-receptor antagonist;
histamine agonist;
sedative;
serotonergic antagonist
mirtazapine
Mirtazapine: A piperazinoazepine tetracyclic compound that enhances the release of NOREPINEPHRINE and SEROTONIN through blockage of presynaptic ALPHA-2 ADRENERGIC RECEPTORS. It also blocks both 5-HT2 and 5-HT3 serotonin receptors and is a potent HISTAMINE H1 RECEPTOR antagonist. It is used for the treatment of depression, and may also be useful for the treatment of anxiety disorders.		2.0510benzazepine;
tetracyclic antidepressant		alpha-adrenergic antagonist;
anxiolytic drug;
H1-receptor antagonist;
histamine antagonist;
oneirogen;
serotonergic antagonist
pioglitazone
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.. pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.		3.4311aromatic ether;
pyridines;
thiazolidinediones		antidepressant;
cardioprotective agent;
EC 2.7.1.33 (pantothenate kinase) inhibitor;
EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor;
ferroptosis inhibitor;
geroprotector;
hypoglycemic agent;
insulin-sensitizing drug;
PPARgamma agonist;
xenobiotic
corticosterone
[no description available]		1.961011beta-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone		human metabolite;
mouse metabolite
prednisolone
Prednisolone: A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states.. prednisolone : A glucocorticoid that is prednisone in which the oxo group at position 11 has been reduced to the corresponding beta-hydroxy group. It is a drug metabolite of prednisone.		2.131011beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		adrenergic agent;
anti-inflammatory drug;
antineoplastic agent;
drug metabolite;
environmental contaminant;
immunosuppressive agent;
xenobiotic
spironolactone
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827). spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.		1.99103-oxo-Delta(4) steroid;
oxaspiro compound;
steroid lactone;
thioester		aldosterone antagonist;
antihypertensive agent;
diuretic;
environmental contaminant;
xenobiotic
aldosterone
[no description available]		2.031011beta-hydroxy steroid;
18-oxo steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
C21-steroid hormone;
mineralocorticoid;
primary alpha-hydroxy ketone;
steroid aldehyde		human metabolite;
mouse metabolite
tetrahydrocortisol
[no description available]		6.3438111beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3alpha-hydroxy steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone
tetrahydrocortisone
[no description available]		4.5926021-hydroxy steroid
androsterone
[no description available]		4.888117-oxo steroid;
3alpha-hydroxy steroid;
androstanoid;
C19-steroid		androgen;
anticonvulsant;
human blood serum metabolite;
human metabolite;
human urinary metabolite;
mouse metabolite;
pheromone
etiocholanolone
Etiocholanolone: The 5-beta-reduced isomer of ANDROSTERONE. Etiocholanolone is a major metabolite of TESTOSTERONE and ANDROSTENEDIONE in many mammalian species including humans. It is excreted in the URINE.. 3alpha-hydroxy-5beta-androstan-17-one : An androstanoid that is 5beta-androstane substituted by an alpha-hydroxy group at position 3 and an oxo group at position 17. It is a metabolite of testosterone in mammals.		4.767117-oxo steroid;
3alpha-hydroxy steroid;
androstanoid		human metabolite;
mouse metabolite
androstenedione
Androstenedione: A delta-4 C19 steroid that is produced not only in the TESTIS, but also in the OVARY and the ADRENAL CORTEX. Depending on the tissue type, androstenedione can serve as a precursor to TESTOSTERONE as well as ESTRONE and ESTRADIOL.. androst-4-ene-3,17-dione : A 3-oxo Delta(4)-steroid that is androst-4-ene substituted by oxo groups at positions 3 and 17. It is a steroid hormone synthesized in the adrenal glands and gonads.		1.961017-oxo steroid;
3-oxo-Delta(4) steroid;
androstanoid		androgen;
Daphnia magna metabolite;
human metabolite;
mouse metabolite
cyclohexanol
Cyclohexanols: Monohydroxy derivatives of cyclohexanes that contain the general formula R-C6H11O. They have a camphorlike odor and are used in making soaps, insecticides, germicides, dry cleaning, and plasticizers.. cyclohexanols : An alcohol in which one or more hydroxy groups are attached to a cyclohexane skeleton.		2.0510cyclohexanols;
secondary alcohol		solvent
diethylhexyl phthalate
Diethylhexyl Phthalate: An ester of phthalic acid. It appears as a light-colored, odorless liquid and is used as a plasticizer for many resins and elastomers.. bis(2-ethylhexyl) phthalate : A phthalate ester that is the bis(2-ethylhexyl) ester of benzene-1,2-dicarboxylic acid.		2.110diester;
phthalate ester		androstane receptor agonist;
apoptosis inhibitor;
plasticiser
monobutyl phthalate
monobutyl phthalate: RN given refers to parent cpd		2.110phthalic acid monoester
epitestosterone
Epitestosterone: The 17-alpha isomer of TESTOSTERONE, derived from PREGNENOLONE via the delta5-steroid pathway, and via 5-androstene-3-beta,17-alpha-diol. Epitestosterone acts as an antiandrogen in various target tissues. The ratio between testosterone/epitestosterone is used to monitor anabolic drug abuse.. epitestosterone : An androstanoid that is the C-17 epimer of testosterone.		2.11017alpha-hydroxy steroid;
3-oxo-Delta(4) steroid;
androstanoid		androgen antagonist;
human metabolite
dihydrotestosterone
Dihydrotestosterone: A potent androgenic metabolite of TESTOSTERONE. It is produced by the action of the enzyme 3-OXO-5-ALPHA-STEROID 4-DEHYDROGENASE.. 17beta-hydroxyandrostan-3-one : A 17beta-hydroxy steroid that is testosterone in which the 4-5 double bond has been reduced to a single bond with unspecified configuration at position 5.. 17beta-hydroxy-5alpha-androstan-3-one : A 17beta-hydroxy steroid that is testosterone in which the 4,5 double bond has been reduced to a single bond with alpha-configuration at position 5.		2.382017beta-hydroxy steroid;
17beta-hydroxyandrostan-3-one;
3-oxo-5alpha-steroid		androgen;
Daphnia magna metabolite;
human metabolite;
mouse metabolite
mono-(2-ethylhexyl)phthalate
mono-(2-ethylhexyl)phthalate: RN given refers to parent cpd. mono(2-ethylhexyl) phthalate : The mono(2-ethylhexyl) ester of benzene-1,2-dicarboxylic acid.		2.110phthalic acid monoester
danazol
Danazol: A synthetic steroid with antigonadotropic and anti-estrogenic activities that acts as an anterior pituitary suppressant by inhibiting the pituitary output of gonadotropins. It possesses some androgenic properties. Danazol has been used in the treatment of endometriosis and some benign breast disorders.		21017beta-hydroxy steroid;
terminal acetylenic compound		anti-estrogen;
estrogen antagonist;
geroprotector
androstane-3,17-diol
Androstane-3,17-diol: The unspecified form of the steroid, normally a major metabolite of TESTOSTERONE with androgenic activity. It has been implicated as a regulator of gonadotropin secretion.		2.372017-hydroxy steroid;
3-hydroxy steroid;
androstanoid
finasteride
Finasteride: An orally active 3-OXO-5-ALPHA-STEROID 4-DEHYDROGENASE inhibitor. It is used as a surgical alternative for treatment of benign PROSTATIC HYPERPLASIA.. finasteride : An aza-steroid that is a synthetic drug for the treatment of benign prostatic hyperplasia.		1.97103-oxo steroid;
aza-steroid;
delta-lactam		androgen antagonist;
antihyperplasia drug;
EC 1.3.1.22 [3-oxo-5alpha-steroid 4-dehydrogenase (NADP(+))] inhibitor
venlafaxine hydrochloride
Venlafaxine Hydrochloride: A cyclohexanol and phenylethylamine derivative that functions as a SEROTONIN AND NORADRENALINE REUPTAKE INHIBITOR (SNRI) and is used as an ANTIDEPRESSIVE AGENT.		2.0510hydrochloride
tetrahydrocorticosterone
tetrahydrocorticosterone: RN given refers to (3alpha,5beta,11beta)-isomer		1.961021-hydroxy steroid
tetrahydro-11-deoxycortisol
tetrahydro-11-deoxycortisol: (3alpha,5beta)-isomer has angiostatic activity		21021-hydroxy steroid
11-hydroxyandrostenedione
11-hydroxyandrostenedione: RN given refers to cpd without isomeric designation		1.96103-hydroxy steroidandrogen
mono(2-ethyl-5-oxohexyl)phthalate
mono(2-ethyl-5-oxohexyl)phthalate: structure given in first source. mono(2-ethyl-5-oxohexyl) phthalate : A phthalic acid monoester obtained by formal condensation of one of the carboxy groups of phthalic acid with the hydroxy group of 2-ethyl-5-oxohexan-1-ol.		2.110methyl ketone;
phthalic acid monoester		human urinary metabolite;
human xenobiotic metabolite
cortolone
[no description available]		7.362021-hydroxy steroid
mono(2-ethyl-5-hydroxyhexyl) phthalate
mono(2-ethyl-5-hydroxyhexyl) phthalate: a metabolite of bis(2-ethylhexyl) phthalate. mono(2-ethyl-5-hydroxyhexyl) phthalate : A phthalic acid monoester obtained by formal condensation of one of the carboxy groups of phthalic acid with the primary hydroxy group of 2-ethylhexane-1,5-diol		2.110phthalic acid monoesterhuman urinary metabolite;
human xenobiotic metabolite
cortisone
[no description available]		3.7911011-oxo steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		human metabolite;
mouse metabolite
cortol
[no description available]		1.981021-hydroxy steroid
cortodoxone
Cortodoxone: 17,21-Dihydroxypregn-4-ene-3,20-dione. A 17-hydroxycorticosteroid with glucocorticoid and anti-inflammatory activities.. 11-deoxycortisol : A deoxycortisol that is cortisol in which the hydroxy group at position 11 has been replaced by a hydrogen.		210deoxycortisol;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		human metabolite;
mouse metabolite
carbenoxolone sodium
Carbenoxolone: An agent derived from licorice root. It is used for the treatment of digestive tract ulcers, especially in the stomach. Antidiuretic side effects are frequent, but otherwise the drug is low in toxicity.		1.9710triterpenoid
androstane-3,17-diol glucuronide
androstane-3,17-diol glucuronide: RN given refers to cpd with unspecified glucuronide locant		1.9710steroid ester
pregnanediol
[no description available]		1.9310
11 beta-hydroxyandrosterone
11 beta-hydroxyandrosterone: RN given refers to (3alpha,5alpha,11beta)-isomer; structure		1.96103-hydroxy steroidandrogen
18-hydroxycortisol
18-hydroxycortisol: from urine of patients with primary aldosteronism. 18-hydroxycortisol : A 18-hydroxy steroid that is cortisol carrying a hydroxy group at position 18. Its urinary excretion is increased in patients with aldosterone-producing adenoma.		2.0310
18-oxocortisol
18-oxocortisol: biosynthesized by aldosterone-producing adrenal tissue; structure given in first source. 18-oxocortisol : A steroid aldehyde that is cortisol carrying a formyl group at position 18.		2.0310
ConditionIndicatedRelationship StrengthStudiesTrials
Acute Porphyria
[description not available]		02.0810
Porphyria, Acute Intermittent
An autosomal dominant porphyria that is due to a deficiency of HYDROXYMETHYLBILANE SYNTHASE in the LIVER, the third enzyme in the 8-enzyme biosynthetic pathway of HEME. Clinical features are recurrent and life-threatening neurologic disturbances, ABDOMINAL PAIN, and elevated level of AMINOLEVULINIC ACID and PORPHOBILINOGEN in the urine.		02.0810
Affective Psychosis, Bipolar
[description not available]		02.110
Dementia Praecox
[description not available]		02.110
Bipolar Disorder
A major affective disorder marked by severe mood swings (manic or major depressive episodes) and a tendency to remission and recurrence.		02.110
Schizophrenia
A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior.		02.110
Hepatocellular Carcinoma
[description not available]		02.110
Cirrhosis, Liver
[description not available]		02.110
Cancer of Liver
[description not available]		02.110
Carcinoma, Hepatocellular
A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.		02.110
Liver Cirrhosis
Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.		02.110
Liver Neoplasms
Tumors or cancer of the LIVER.		02.110
Depression, Involutional
Form of depression in those MIDDLE AGE with feelings of ANXIETY.		02.4820
Depressive Disorder, Major
Disorder in which five (or more) of the following symptoms have been present during the same 2-week period and represent a change from previous functioning; at least one of the symptoms is either (1) depressed mood or (2) loss of interest or pleasure. Symptoms include: depressed mood most of the day, nearly every daily; markedly diminished interest or pleasure in activities most of the day, nearly every day; significant weight loss when not dieting or weight gain; Insomnia or hypersomnia nearly every day; psychomotor agitation or retardation nearly every day; fatigue or loss of energy nearly every day; feelings of worthlessness or excessive or inappropriate guilt; diminished ability to think or concentrate, or indecisiveness, nearly every day; or recurrent thoughts of death, recurrent suicidal ideation without a specific plan, or a suicide attempt. (DSM-5)		02.4820
Malnourishment
[description not available]		02.0510
Acute Post-Traumatic Stress Disorder
[description not available]		02.0510
Aging
The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.		02.6430
Stress Disorders, Post-Traumatic
A class of traumatic stress disorders with symptoms that last more than one month.		02.0510
Malnutrition
An imbalanced nutritional status resulting from insufficient intake of nutrients to meet normal physiological requirement.		02.0510
Chronic Kidney Diseases
[description not available]		02.0710
Hypertension, Renal
Persistent high BLOOD PRESSURE due to KIDNEY DISEASES, such as those involving the renal parenchyma, the renal vasculature, or tumors that secrete RENIN.		02.0710
Renal Insufficiency, Chronic
Conditions in which the KIDNEYS perform below the normal level for more than three months. Chronic kidney insufficiency is classified by five stages according to the decline in GLOMERULAR FILTRATION RATE and the degree of kidney damage (as measured by the level of PROTEINURIA). The most severe form is the end-stage renal disease (CHRONIC KIDNEY FAILURE). (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002)		02.0710
Inappropriate GH Secretion Syndrome (Acromegaly)
[description not available]		02.0210
Acromegaly
A condition caused by prolonged exposure to excessive HUMAN GROWTH HORMONE in adults. It is characterized by bony enlargement of the FACE; lower jaw (PROGNATHISM); hands; FEET; HEAD; and THORAX. The most common etiology is a GROWTH HORMONE-SECRETING PITUITARY ADENOMA. (From Joynt, Clinical Neurology, 1992, Ch36, pp79-80)		02.0210
Adrenal Cortex Diseases
Pathological processes of the ADRENAL CORTEX.		02.0310
Sensitivity and Specificity
Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)		02.0410
Insulin Sensitivity
[description not available]		03.4311
Polycystic Ovarian Syndrome
[description not available]		03.4311
Insulin Resistance
Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS.		03.4311
Polycystic Ovary Syndrome
A complex disorder characterized by infertility, HIRSUTISM; OBESITY; and various menstrual disturbances such as OLIGOMENORRHEA; AMENORRHEA; ANOVULATION. Polycystic ovary syndrome is usually associated with bilateral enlarged ovaries studded with atretic follicles, not with cysts. The term, polycystic ovary, is misleading.		03.4311
Cushing's Syndrome
[description not available]		02.3820
Cushing Syndrome
A condition caused by prolonged exposure to excess levels of cortisol (HYDROCORTISONE) or other GLUCOCORTICOIDS from endogenous or exogenous sources. It is characterized by upper body OBESITY; OSTEOPOROSIS; HYPERTENSION; DIABETES MELLITUS; HIRSUTISM; AMENORRHEA; and excess body fluid. Endogenous Cushing syndrome or spontaneous hypercortisolism is divided into two groups, those due to an excess of ADRENOCORTICOTROPIN and those that are ACTH-independent.		02.3820
Breast Diseases
Pathological processes of the BREAST.		01.9510
Breast Cancer
[description not available]		01.9510
Breast Neoplasms
Tumors or cancer of the human BREAST.		01.9510
Alcohol Abuse
[description not available]		02.3820
Alcoholic Liver Diseases
[description not available]		01.9810
Alcoholism
A primary, chronic disease with genetic, psychosocial, and environmental factors influencing its development and manifestations. The disease is often progressive and fatal. It is characterized by impaired control over drinking, preoccupation with the drug alcohol, use of alcohol despite adverse consequences, and distortions in thinking, most notably denial. Each of these symptoms may be continuous or periodic. (Morse & Flavin for the Joint Commission of the National Council on Alcoholism and Drug Dependence and the American Society of Addiction Medicine to Study the Definition and Criteria for the Diagnosis of Alcoholism: in JAMA 1992;268:1012-4)		02.3820
Liver Diseases, Alcoholic
Liver diseases associated with ALCOHOLISM. It usually refers to the coexistence of two or more subentities, i.e., ALCOHOLIC FATTY LIVER; ALCOHOLIC HEPATITIS; and ALCOHOLIC CIRRHOSIS.		01.9810
Failure to Thrive
A condition of substandard growth or diminished capacity to maintain normal function.		01.9910
Fetal Growth Restriction
[description not available]		01.9910
Blood Pressure, High
[description not available]		02.6730
Kidney Stones
[description not available]		01.9910
Fetal Growth Retardation
Failure of a FETUS to attain expected GROWTH.		01.9910
Hypertension
Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.		02.6730
Kidney Calculi
Stones in the KIDNEY, usually formed in the urine-collecting area of the kidney (KIDNEY PELVIS). Their sizes vary and most contains CALCIUM OXALATE.		01.9910
Pregnancy
The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.		01.9910
Hirsutism
A condition observed in WOMEN and CHILDREN when there is excess coarse body hair of an adult male distribution pattern, such as facial and chest areas. It is the result of elevated ANDROGENS from the OVARIES, the ADRENAL GLANDS, or exogenous sources. The concept does not include HYPERTRICHOSIS, which is an androgen-independent excessive hair growth.		02.3820
Depression
Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders.		01.9910
Cancer of Prostate
[description not available]		01.9510
Prostatic Neoplasms
Tumors or cancer of the PROSTATE.		01.9510
Hypospadias
A birth defect due to malformation of the URETHRA in which the urethral opening is below its normal location. In the male, the malformed urethra generally opens on the ventral surface of the PENIS or on the PERINEUM. In the female, the malformed urethral opening is in the VAGINA.		01.9710
Ambiguous Genitalia
[description not available]		02.3720
Disorders of Sex Development
In gonochoristic organisms, congenital conditions in which development of chromosomal, gonadal, or anatomical sex is atypical. Effects from exposure to abnormal levels of GONADAL HORMONES in the maternal environment, or disruption of the function of those hormones by ENDOCRINE DISRUPTORS are included.		02.3720